Divestiture • Life Science

Domain Therapeutics Acquires Prestwick Chemical

On December 11, 2019, Domain Therapeutics acquired life science company Prestwick Chemical from Neuphoria

Acquisition Context
  • This is Domain Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Domain Therapeutics’ 2nd transaction in France.

Explore All 789 Divestiture Life Science Deals - Search the Database Free


M&A Deal Summary

Date December 11, 2019
Target Prestwick Chemical
Sector Life Science
Buyer(s) Domain Therapeutics
Sellers(s) Neuphoria
Deal Type Divestiture

Target Company

Prestwick Chemical

Illkirch, France
Prestwick Chemical, Inc. is a provider of medicinal chemistry services and smart screening libraries. The company specializes in research and development services in early drug discovery including hit identification and validation, hit to lead, and lead optimization based on its expertise and state-of-the-art computational technology. Prestwick Chemical was formed in 1999 and is based in Illkirch, France.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Domain Therapeutics

Illkirch Stratsbourg, France

Category Company
Sector Life Science
DESCRIPTION

Domain Therapeutics discovery and development of new medicine for the treatment of chronic neruodegenerative diseases. Domain Therapeutics is based in Illkirch Stratsbourg, France.


Deal Context for Buyer #
Overall 2 of 2
Sector: Life Science 2 of 2
Type: Divestiture 2 of 2
Country: France 2 of 2
Year: 2019 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-12-11 Neurofit SAS

Illkirch-Graffenstaden, France

Neurofit SAS is a pre-clinical CRO offering a comprehensive list of disease models and screening assays in the fields of psychiatry, neurology, multiple sclerosis, diabetes, and pain. The company’s core expertise in CNS and PNS includes animal behavior techniques, nerve conduction velocity measure, nerve fiber morphometry, primary neuronal cell cultures. Neurofit has long-standing experiences in psychiatric, neurodegenerative and autoimmune/inflammatory disorders. Our disease models are clinically relevant and predictive. Neurofit was formed in 1996 and is based in Illkirch-Graffenstaden, France.

Buy -

Seller Profile 1

SELLER

Neuphoria

Burlington, Massachusetts, United States

Category Company
Founded 1996
Sector Life Science
Revenue 4M AUD (2019)
DESCRIPTION

Neuphoria is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's disease. Neuphoria was founded in 1996 and is headquartered in Burlington, Massachusetts.


Deal Context for Seller #
Overall 2 of 2
Sector: Life Science 2 of 2
Type: Divestiture 2 of 2
Country: France 2 of 2
Year: 2019 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-12-11 Neurofit SAS

Illkirch-Graffenstaden, France

Neurofit SAS is a pre-clinical CRO offering a comprehensive list of disease models and screening assays in the fields of psychiatry, neurology, multiple sclerosis, diabetes, and pain. The company’s core expertise in CNS and PNS includes animal behavior techniques, nerve conduction velocity measure, nerve fiber morphometry, primary neuronal cell cultures. Neurofit has long-standing experiences in psychiatric, neurodegenerative and autoimmune/inflammatory disorders. Our disease models are clinically relevant and predictive. Neurofit was formed in 1996 and is based in Illkirch-Graffenstaden, France.

Sell -

Explore Related M&A Activity